The SCIL-STROKE (Subcutaneous Interleukin-1 Receptor Antagonist in Ischemic Stroke)—a single-center, randomized, double blind, controlled, phase II study—confirmed tolerability, safety and the effect of IL-1 antagonism on inflammatory mediators upon stroke [16]. Here, IL1A is linked to ischemic stroke.